Integrins are a superfamily of transmembrane cell surface receptors that mediate signal transduction, cell-to-cell interaction, and cell-to-extracellular matrix adhesion - key processes for healthy cells as well as progression of disease states such as atherosclerosis and cancer, where integrins contribute to angiogenesis, tumorigenesis, and metastasis.
Among this superfamily, αvβ3 integrin holds promise as a therapeutic target in areas such as immuno-oncology, where αvβ3 integrin may prevent tumors from evading the immune system. PerkinElmer's IntegriSense™ fluorescence probes are designed to target αvβ3 integrin for monitoring tumor growth, angiogenesis and assessing treatment efficacy.
For laboratory use only. This product is intended for animal research only and not for use in humans.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
IntegriSense 645 fluorescent imaging agent for in vivo detection of αvβ3 integrin is a low molecular weight peptidomimetic antagonist coupled to a red fluorochrome. This validated, high affinity (Kd = 4.2 nM) fluorescent probe has improved circulation half-life and specificity over RDG peptide-based agents, with selectivity 5-20x for αvβ3 integrin, for precise detection of αvβ3 integrins. IntegriSense 645 integrin-targeted molecular imaging agent allows non-invasive imaging to better understand biological pathways, and disease biology and progression.
Including IntegriSense 645 fluorescent probe in careful experimental design allows for multiplexing with other channels and/or imaging times, and can be paired with other probes to achieve maximum efficiency and flexibility in your imaging studies.
|Fluorescent Agent Type||Targeted|
|Optical Imaging Classification||Fluorescence Imaging|
|Product Brand Name||IntegriSense|
|Quantity in a Package Amount||1.0 Units|
|Shipping Condition||Blue Ice|
|Therapeutic Area||Angiogenesis, Atherosclerosis, Oncology/Cancer|
|Unit Size||1 Vial (10 doses)|
|Wave Length||645 nm|
Current means of measuring disease in preclinical models of atherosclerosis include ex vivo assessment of disease tissues post-mortem and non-invasive imaging primarily of structural and anatomic features of lesions, in vivo. A non-invasive, quantitative means of imaging known biologic profiles associated with atherosclerotic disease, in vivo, would enable a robust additional understanding and analysis of disease progression and therapeutic response in research and drug development. We report the utility of the near infrared (NIR) protease-sensing, ProSense® 750 Fluorescent Pre-clinical Imaging Agent, in combination with the FMT® 2500 Quantitative Pre-clinical Imaging System for the non-invasive quantitative measurement of atherosclerotic disease biology and related response to therapy in apolipoprotein (apo) E-deficient mice in vivo. FMT (Fluorescence Molecular Tomography) imaging measured significant increases in aortic region protease activity with a range of values that were comparable to the range seen in the ex vivo aortic arches assessed by fluorescence reflectance imaging (FRI).
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.
Integrins are a superfamily of transmembrane cell surface receptors that mediate signal transduction, cell-to-cell interaction, and cell-to-extracellular matrix adhesion - key processes for healthy cells as well as in the progression of disease states such as cancer.
Among this superfamily, αvβ3 integrin holds promise as a therapeutic target in areas such as immuno-oncology, where it may enable tumors to evade the immune system. PerkinElmer's IntegriSense™ fluorescent probes are designed to target αvβ3 integrin to help researchers better understand how cancer cells hijack normal integrin-related cell signaling and cell adhesion processes that promote tumor growth and metastases, as well as investigating the potential of integrin-blocking cancer immunotherapies.
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.